Australia's TGA consults on proposed overhaul of OTC drug guidelines
This article was originally published in SRA
Australia's Therapeutic Goods Administration is inviting comments on its proposal to substantially revise its guidance document for over-the-counter medicines1. The revisions are being made to clarify the data requirements for submitting OTC medicine applications to the TGA and to provide guidance on OTC drug market authorisation processes that are also currently being reviewed.
You may also be interested in...
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.
Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. While the European Medicines Agency has launched an investigation, Australia is examining the need for specific warnings about risks of vaccination in the very frail elderly or terminally ill patients.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.